Mark Hopman Sells 856 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 856 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $29.34, for a total value of $25,115.04. Following the completion of the sale, the insider directly owned 138,277 shares of the company’s stock, valued at approximately $4,057,047.18. This represents a 0.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, March 4th, Mark Hopman sold 353 shares of Beta Bionics stock. The shares were sold at an average price of $11.57, for a total transaction of $4,084.21.
• On Monday, March 2nd, Mark Hopman sold 834 shares of Beta Bionics stock. The shares were sold at an average price of $12.36, for a total transaction of $10,308.24.

Beta Bionics Stock Up 4.6%

BBNX stock traded up $0.48 during trading on Monday, reaching $10.87. The company had a trading volume of 911,515 shares, compared to its average volume of 1,199,208. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The firm has a 50-day simple moving average of $15.15 and a 200-day simple moving average of $22.01.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Beta Bionics in the first quarter valued at $95,000. Goldman Sachs Group Inc. purchased a new position in shares of Beta Bionics during the 1st quarter valued at about $715,000. Woodline Partners LP purchased a new position in shares of Beta Bionics during the 1st quarter valued at about $1,530,000. Strs Ohio acquired a new position in shares of Beta Bionics in the 1st quarter valued at about $29,000. Finally, Rhumbline Advisers purchased a new stake in shares of Beta Bionics in the first quarter worth about $158,000.

Analysts Set New Price Targets

BBNX has been the topic of several research reports. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Stifel Nicolaus dropped their price target on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. TD Cowen started coverage on Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective on the stock. Robert W. Baird reduced their price objective on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Finally, Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.20.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.